SCHEMBL855300

SCHEMBL855300

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NNC(=O)c3ccccc3)ccc1C)c(=O)n2C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.49
KMT2A Q03164 5/20 0.40
POLB P06746 4/20 0.40
KDM4E B2RXH2 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
BRAF P15056 3/20 0.39
RAF1 P04049 2/20 0.39
FGFR1 P11362 2/20 0.39
SRC P12931 2/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MAPK14 Q16539 2/20 0.38
MAPK13 O15264 1/20 0.38
KDR P35968 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL854572 0.92 SYK (0.49) SYKKMT2AKDM4ETDP1NPC1
SCHEMBL10043850 0.92 SYK (0.50) SYKKMT2APOLBBRAFRAF1
SCHEMBL10043699 0.92 SYK (0.57) SYKKMT2APOLBKDM4EBRAF
SCHEMBL10043821 0.89 SYK (0.49) SYKKMT2APOLBFGFR1SRC
SCHEMBL854945 0.86 NPC1 (0.55) SYKKDM4ENPC1RAB9AMAPT
SCHEMBL10043857 0.85 POLB (0.45) SYKKMT2APOLBFGFR1SRC
SCHEMBL10043705 0.85 MAPT (0.54) SYKKMT2APOLBKDM4ENPC1
SCHEMBL10043828 0.85 RAB9A (0.48) SYKPOLBKDM4EBRAFRAF1
SCHEMBL10043853 0.84 SYK (0.48) SYKKMT2APOLBKDM4EBRAF
SCHEMBL10043826 0.84 MAPK1 (0.45) SYKKMT2ABRAFRAF1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278452-B2 Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors IRM LLC (BM) 2012-10-02 US disclosed
US-8278452-B2 Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors IRM LLC (BM) 2012-10-02 US disclosed
EP-2252612-B1 HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS IRM LLC (BM) 2012-03-28 EP disclosed
US-20110183997-A1 HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS IRM LLC (BM) 2011-07-28 US disclosed
US-20110183997-A1 HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS IRM LLC (BM) 2011-07-28 US disclosed
EP-2252612-A1 HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS IRM LLC (BM) 2010-11-24 EP disclosed
WO-2009105712-A1 HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS IRM LLC (BM) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183997-A1 HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS KIT, PDGFRA, PDGFRB SYK 566/4885KMT2A 1551/4885POLB 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.